Zura Bio (ZURA) Q1 2026 earnings summary

Executive summary

• Advancing tibulizumab in Phase 2 trials for hidradenitis suppurativa and systemic sclerosis, with topline results expected in late 2026 and early 2027, respectively.

• No approved products or product revenue; operations funded by equity financings totaling up to $421.5 million.

• Strengthened leadership with new CEO and Board appointments in early 2026.

• Net loss for Q1 2026 was $24.2 million, up from $17.4 million in Q1 2025, reflecting increased R&D and G&A expenses.

Financial highlights

• Cash and cash equivalents at March 31, 2026: $225.6 million, up from $109.4 million at December 31, 2025, due to a February 2026 equity offering.

• Operating expenses for Q1 2026: $25.5 million (R&D: $14.7 million, G&A: $10.8 million), a 32% increase year-over-year.

• Net loss per share (basic and diluted) for Q1 2026: $0.22, compared to $0.19 in Q1 2025.

Outlook and guidance

• Sufficient liquidity to fund operations through at least the end of 2028 based on current plans and cash position.

• Topline data for hidradenitis suppurativa Phase 2 expected in Q4 2026; systemic sclerosis in H1 2027.

• Anticipates continued increases in operating expenses as clinical programs advance and organization scales.

• No revenue expected from product sales for at least the next few years; ongoing need for additional capital anticipated.